PALI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Palisade Bio Inc (PALI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive analyst ratings and potential catalysts in its pipeline, the lack of significant trading trends, neutral technical indicators, and poor financial performance suggest that this is a speculative investment. The investor may want to monitor the stock for further developments or wait for clearer signals before committing funds.
The MACD is positive and contracting, indicating a weak bullish trend. RSI is neutral at 53.526, showing no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level of 1.985, with resistance at 2.111 and support at 1.859. Overall, the technical indicators suggest a weak bullish trend but no strong entry point.
Analysts have given the stock multiple Buy ratings with high price targets, citing the potential of PALI-2108 in the inflammatory bowel disease market. The drug has shown promising early-stage clinical results, and upcoming pipeline catalysts could drive value.
The company has poor financial performance, with no revenue and a significant net loss (-$8.89M in Q4 2025). EPS has also dropped significantly (-97.42% YoY). Additionally, there is no recent news or significant trading activity from insiders or hedge funds.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$8.89M, though this was an improvement of 166.12% YoY. EPS dropped significantly to -0.04 (-97.42% YoY). The gross margin remains at 0%. Overall, the financials are weak and do not support a strong investment case.
Analysts are optimistic about PALI, with multiple Buy ratings and price targets ranging from $5 to $25. They highlight the potential of PALI-2108 in treating inflammatory bowel disease and fibrostenotic Crohn's disease. However, these ratings are speculative and based on future pipeline success rather than current fundamentals.
